Pharmaceuticals
Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million
SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announc...
2019-10-04 16:11
3350
Successful implementation of ClinSpark® at Phase I unit of a Top-10 Biopharmaceutical company
GRAFTON, Wisconsin, Oct. 2, 2019 /PRNewswire/ -- Following the successful implementation of ClinSpark® at the Phase I unit of a top-10 biopharmaceutical company inEurope, the first study database was locked where the entire trial was conducted within the system. FDA submission-ready eCRFs of all ...
2019-10-02 23:37
953
Clarivate Analytics introduces next-generation pre-clinical drug research platform with Cortellis Drug Discovery Intelligence
Updated solution enables enhanced analytics and greater utility of biology, chemistry and pharmacology data—within a single application LONDON and PHILADELPHIA, Oct. 2, 2019 /PRNewswire/ -- Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted insights and analytics to...
2019-10-02 01:39
8098
CapsCanada Expands Growth to New State-of-the-Art Facility
DANIA BEACH, Florida, Oct. 1, 2019 /PRNewswire/ -- CapsCanada®, the leading innovator of vegetarian K-CAPS®, accelerates growth by relocating their headquarters to a new state-of-the-art facility strategically located in Dania Beach,Florida, with close proximity to two major interstate highways, ...
2019-10-01 19:00
1169
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability
SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) released pooled safety data from the Phase Ib (GEMSTONE-101) study of the Company's anti-PD-L1 antibody CS1001 in a poster presentation at the European Society of Medical Oncology 2019 Con...
2019-09-30 18:29
2053
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
2019-09-30 16:30
2279
Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis
* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...
2019-09-30 15:00
959
Data From Ascensia Diabetes Care Shows High Accuracy of the CONTOUR®PLUS and CONTOUR®PLUS ONE BGMS in Low Blood Glucose Range and Potential Benefits From Using the CONTOUR®PLUS ONE BGMS With the Health2Sync App
HONG KONG, Sept. 30, 2019 /PRNewswire/ -- At the 21st Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Ascensia Diabetes Care has presented data from two studies, one analyzing the accuracy of blood glucose monitoring systems (BGMSs) in the low blood glucose range (LBGR) ...
2019-09-30 09:00
2380
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China
NANJING, China and SEOUL, South Korea, Sept. 27, 2019 /PRNewswire/ -- Simcere Pharmaceutical Group and JW Pharmaceutical (KRX:001060, hereinafter called "JWP") announced a collaboration and exclusive license agreement for anti-gout drug candidate URC-102 inChina (including Chinese Hongkong & Maca...
2019-09-27 18:52
4521
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Not intended for US, Canada and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part o...
2019-09-27 14:00
2018
New Clarivate Analytics report shows the cost to bring a drug to market has decreased to under $2B for the first time in over five years
Pharmaceutical R&D industry report provides insights into what's behind decade-high drug approval rates and reveals implications of costs and sustainability LONDON and PHILADELPHIA, Sept. 26, 2019 /PRNewswire/ -- Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted in...
2019-09-26 21:00
6505
Thermo Fisher Scientific Expands Clinical Trials Capabilities and Announces Collaboration with Frontier Biotechnologies Inc.
SUZHOU, China, Sept. 26, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, announced today an expansion of its integrated clinical trials supply and distribution services network, in Suzhou,China, as well as a collaboration with Frontier Biotechnologies Inc. to d...
2019-09-26 14:00
3585
OrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent
HONG KONG, Sept. 26, 2019 /PRNewswire/ -- OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] t...
2019-09-26 01:01
1551
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA's approval of the oral formulation of Akynzeo(R) in China
LUGANO, Switzerland and BEIJING, Sept. 25, 2019 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical Products Administrat...
2019-09-25 12:11
3383
Supply Chain Digitization Creates New Revenue Opportunities in the Vaccine Market
High investment in adult immunization and innovations in DNA vaccines will rejuvenate the vaccines market, finds Frost & Sullivan SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- The need for improved immunogenicity, delivery technologies and reliable supply are driving the shift from the...
2019-09-24 23:28
2071
Global Pharmaceutical Functional and Multifunctional Excipients Industry to Cross the $10 Billion Mark by 2023
SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- Frost & Sullivan's latest analysis,Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023, reveals that the development of innovative drug delivery technologies, a growing generic and biosimilar drug market,...
2019-09-24 22:45
1648
PolyU develops a new class of antibiotic candidates for fighting against superbugs
HONG KONG, Sept. 24, 2019 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) has developed a new class of antibiotic drug candidates which has high potential to be developed into a new generation of antibiotics fighting against multi-drug resistant superbugs including methicillin-resist...
2019-09-24 17:46
2090
CPhI recruiting freelance pharmaceutical authors contributing to the global industry professionals
SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry globally. As the initiator of an Internet platform for knowledge sharing in the pharmaceutical field, CPhI.CN aims to create hot industry content to achieve effective commu...
2019-09-23 17:56
1749
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455,Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. * N...
2019-09-23 14:00
2714
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors
SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...
2019-09-22 14:22
1616
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 325 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 306 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 276 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
11042
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
9485
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
8967
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
8270
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7515
